Immix Biopharma Inc
$ 10.09
-2.51%
20 Apr - close price
- Market Cap 534,892,000 USD
- Current Price $ 10.09
- High / Low $ 10.35 / 9.87
- Stock P/E N/A
- Book Value 1.77
- EPS -0.89
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -0.55 %
- 52 Week High 11.61
- 52 Week Low 1.64
About
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California.
Analyst Target Price
$17.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-12-03 | 2025-09-03 | 2025-05-07 | 2025-02-26 | 2024-11-09 | 2024-08-11 | 2024-05-09 | 2024-03-29 | 2023-11-13 | 2023-08-11 | 2023-05-12 |
| Reported EPS | -0.28 | -0.24 | -0.22 | -0.15 | -0.25 | -0.24 | -0.15 | -0.2244 | -0.23 | -0.23 | -0.24 | -0.18 |
| Estimated EPS | -0.15 | -0.16 | -0.21 | -0.23 | -0.25 | -0.16 | -0.21 | -0.23 | -0.23 | -0.23 | -0.17 | -0.14 |
| Surprise | -0.13 | -0.08 | -0.01 | 0.08 | 0 | -0.08 | 0.06 | 0.0056 | 0 | 0 | -0.07 | -0.04 |
| Surprise Percentage | -86.6667% | -50% | -4.7619% | 34.7826% | 0% | -50% | 28.5714% | 2.4348% | 0% | 0% | -41.1765% | -28.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.21 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMMX
2026-04-20 09:10:00
The article states that Immix Biopharma's (IMMX) price target has been increased by 50.00% to $12.24. No further details are provided in the current content.
2026-04-16 16:39:23
Immix Biopharma (NASDAQ:IMMX) saw its stock price drop by 4.6% during intraday trading, with unusually low volume. The company, a clinical-stage immuno-oncology firm, traded at $9.57 and currently has a market capitalization of $521 million. Analyst ratings are mixed, with a consensus of "Moderate Buy" but individual price targets ranging widely, and the company recently missed Q1 EPS estimates while institutional ownership remains low at about 11%.
2026-04-13 18:40:01
The article reports that the price target for Immix Biopharma (IMMX) has been increased by 11.73%, bringing it to $18.62. This suggests a positive outlook for the company's stock from analysts.
2026-04-12 07:40:38
This page provides a compilation of recent news and upcoming events related to Immix Biopharma (IMMX). Key updates include an "Overweight" rating from Morgan Stanley, FDA Breakthrough Therapy Designation for NXC-201, and the completion of NEXICART-2 enrollment with topline results anticipated in Q3 2026. The company also announced a $750 million shelf registration for stock offerings and the appointment of Richard Graydon as chief medical officer.
2026-04-10 11:09:33
This article reports that the price target for Immix Biopharma (IMMX) has been increased by 11.73%, bringing it to $18.62. No further details are provided in this brief update.
2026-04-10 05:40:11
This article reports on an Annual Report to Shareholders (ARS) SEC filing by Immix Biopharma, Inc. (IMMX) on April 6, 2026. The filing has a low impact and neutral sentiment, and a PDF version is available. The report also includes recent news, SEC filings, and stock data for Immix Biopharma.
